Clinical Trial Update: Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD) [Phase 1]

View source ↗

Summary

Phase 1 safety and pharmacodynamic study of sobetirome in X-linked adrenoleukodystrophy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenomyeloneuropathy
• X-linked Adrenoleukodystrophy

Drugs mentioned

• Sobetirome (sobetirome)

Snippet

Sponsor: Thomas S. Scanlan | Conditions: X-Linked Adrenoleukodystrophy, Adrenomyeloneuropathy | Phase 1 | Status: WITHDRAWN